EUVIMEDEUVIMED entdecken
Multizentrische Studie

The COR Lipid Registry: the effectiveness of the strike early and strike strong strategy in patients with high cardiovascular risk

Patrick Weltler iD, Paul F Harbich, Achim Burger, Stephan Dobner, Christoph C Kaufmann, Alexander Geppert, Kurt Huber iD, Edita Pogran

European Heart Journal: Acute Cardiovascular Care · 2025

DOI: 10.1093/ehjacc/zuaf137 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift European Heart Journal: Acute Cardiovascular Care, 2025. Verfasst von Patrick Weltler und 7 weiteren Autor:innen. Beteiligte Einrichtung: 3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring, Montleartstaße 37, 1160 Vienna, Austria. Hauptthemen laut MEDLINE: Registries, Cholesterol, LDL, Cardiovascular Diseases, Acute Coronary Syndrome. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

According to real-world data, only up to 20% of patients with atherosclerotic cardiovascular disease (ASCVD) are below the recommended LDL-cholesterol (LDL-C) target of <55 mg/dL (<1.4 mmol/L) 1–3 months after the index event. Accordingly, improved strategies for initiating lipid-lowering therapy (LLT) are desired to achieve treatment targets required to further reduce future cardiovascular event rates. Methods and results The COR Lipid Registry included patients at very high cardiovascular (CV) risk presenting for percutaneous coronary intervention (PCI) with acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Coronary artery disease (CAD) patients with an LDL-C level of >130 mg/dL (equalizing 3.37 mmol/L) or a non-HDL of 160 mg/dL (equalizing 4.14 mmol/L) either LLT-naïve or with suboptimal LLT at index hospitalization were enrolled. Based on lipid levels at baseline, these patients were assumed to need triple LLT to achieve their LDL-C target. Baseline characteristics and lipid parameters of all patients were collected at index hospitalization and two follow-up visits, after 4–6 and 8–12 weeks, respectively. Initially, in all patients a dual LLT (high-dose, highly effective statin, which means atorvastatin 40 mg or 80 mg and rosuvastatin 20 mg or 40 mg, plus ezetimibe) was initiated during the index hospitalization, before PCSK9 inhibitors or bempedoic acid were added, if LDL-C target levels were not met at control visits. In total, 165 very high-risk patients were included, of which 79 (42.0%) were admitted for CCS and 109 (58%) for ACS, respectively. At Visit 1, 114 (69.1%) patients reached the recommended (ESC/EAS guidelines 2019) lipid goals (LDL-C of < 55 mg/dL; equalizing 1.4 mmol/L; or non-HDL-C of 85 mg/dL equalizing 2.2 mmol/<L), while 160 patients (97%) met the target at Visit 2. In ACS patients, 74.3% reached the recommended treatment goal (LDL-C or non-HDL-C) at Visit 1 and 97.3% at Visit 2. In CCS patients, the treatment goal was achieved in 60.8% at Visit 1 and 100% at Visit 2, respectively. In the LLT-naïve group at admission (n = 64), the treatment goal was met in 61.5% of patients at Visit 1 and in 96.9% of patients at Visit 2, while for LLT-pre-treated patients, the respective data were 76.3% and 100%, respectively.

Conclusion

An optimized LLT strategy for managing a very high CV risk patient cohort undergoing PCI, starting with a dual LLT strategy consisting of a high-dose, highly effective statin plus ezetimibe at the index event followed by addition of a third LL-agent (a PCSK9 inhibitor or bempedoic acid) at follow-up after 4–6 weeks if treatment goal was not reached, was highly effective in achieving LDL-C and non-HDL-C goals. Wider adoption of this strategy may help to significantly improve LDL-C target levels in real-world populations in very high-risk CAD patients presenting with ACS or CCS for coronary revascularization.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RegistriesCholesterol, LDLCardiovascular DiseasesAcute Coronary SyndromeHumansMaleFemaleAgedMiddle AgedPercutaneous Coronary InterventionHydroxymethylglutaryl-CoA Reductase InhibitorsTreatment OutcomeHeart Disease Risk FactorsFollow-Up Studies

Stichwörter der Autor:innen

ACSAtorvastatineCCSHyperlipidemiaPreventionRosuvastatine

Substanzen

Cholesterol, LDLHydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • 3rd Medical Department for Cardiology and Intensive Care Medicine, Klinik Ottakring, Montleartstaße 37, 1160 Vienna, Austria.
  • Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria.
  • Sigmund Freud University, Faculty of Medicine, Vienna, Austria.
  • Austrian Heart Foundation, Vienna, Austria.

ORCID-Profile: Patrick Weltler, Kurt Huber

Zitieren

APA

Weltler, P., Harbich, P. F., Burger, A., Dobner, S., Kaufmann, C. C., Geppert, A., Huber, K., & Pogran, E. (2025). The COR Lipid Registry: the effectiveness of the strike early and strike strong strategy in patients with high cardiovascular risk. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuaf137

Vancouver

Weltler P, Harbich PF, Burger A, Dobner S, Kaufmann CC, Geppert A, et al. The COR Lipid Registry: the effectiveness of the strike early and strike strong strategy in patients with high cardiovascular risk. European Heart Journal: Acute Cardiovascular Care. 2025. doi:10.1093/ehjacc/zuaf137

BibTeX
@article{Weltler2025,
  author = {Weltler, Patrick and Harbich, Paul F and Burger, Achim and Dobner, Stephan and Kaufmann, Christoph C and Geppert, Alexander and Huber, Kurt and Pogran, Edita},
  title = {The COR Lipid Registry: the effectiveness of the strike early and strike strong strategy in patients with high cardiovascular risk},
  journal = {European Heart Journal: Acute Cardiovascular Care},
  year = {2025},
  doi = {10.1093/ehjacc/zuaf137}
}
Kostenlos starten →